In total, 731 collections of psychoactive products were carried out under the OFDT's SINTES system in 2023, an increase of 17% compared to 2022.
10 thematic workbooks describing the national situation on drugs in France in 2023.
Results of the ESSPRI survey evidence a significant exposure to psychoactive substances among adult male inmates in mainland France, regardless of sentences lengths, irrespective of prison type and criminal status (awaiting trial or convicted).
This year, 132 specialised drug treatment centres (CSAPA) participated in the RECAP survey (common data collection on addictions and treatments), out of a total of around 500 CSAPAs, providing data on more than 210 000 patients.
For the past two decades the Survey on Health and Use on National Defence and Citizenship Day (ESCAPAD) conducted by the OFDT has made it possible to quantify the use of psychoactive substance by 17-year-olds at a regional level.
An overview of the criminal justice responses to offences related to driving under the influence of alcohol or drugs since the 1990s.
Psychoactive substance use among middle school and high school students: results of the EnCLASS 2022 survey.
A total of 623 psychoactive products were collected under the SINTES scheme in 2022, an increase of 18% compared with the previous year.
2022 main observations of the OFDT's TREND scheme, which has been monitoring emerging phenomena and developments in the field of drugs (markets, users) since 1999:
The study on the use of analgesic opioid medicines (EMOA) by the French Monitoring Centre for Drugs and Drug Addiction (OFDT) examines their prescription in general practice and the experiences of who consider themselves to be having difficulty with them in the treatment of chronic pain unrelated to cancer in France.
This report presents a new estimate of the social cost of drugs in France in 2019, following a previous calculation in 2010.
The French Monitoring Centre for Drugs and Drug Addiction (OFDT) publishes the first results of the Study on the use of analgesic opioid medicines (entitled EMOA).
The aim of this document is to present updated data on opioid substitution treatment in France. It is based on the latest available data, the year of which may vary from 2019 to 2022 depending on the source and the treatment period.
In March 2022, the ESCAPAD survey interviewed a representative sample of 23 701 French girls and boys with an average age of 17.4 years.
This report of the RECAP survey (common data collection on addictions and treatments) reviews the main recent changes in the statistics on people with addictive behaviour problems accompanied and cared for by teams from specialised drug treatment centres (CSAPA in French).
Assessment of developments in use and access to care, marked by the health crisis linked to Covid-19.
In 2021, the quantities seized by the police, the gendarmerie and customs have reached unprecedented levels for marijuana, cocaine and even heroin. In addition, the levels of substances circulating the country from cannabis resin and heroin to cocaine and MDMA/ecstasy are high, while retail prices are fairly stable or down slightly.
A total of 32 new synthetic products were identified in France in 2021, with the emergence of synthetic opioids and the progression of synthetic cannabinoids. Among these 32 new identifications, 12 were made from samples collected for SINTES, the French National Detection System of Drugs and Toxic Substances.
The OFDT publishes this issue on the analysis of the practices of addiction treatment workers: what does it mean to work in specialised drug treatment centres (CSAPA) and in harm reduction facilities (CAARUD)?
This 2022 edition provides an overall perspective digest in 8 pages with the most recent and detailed facts and figures.